A phase II/III randomised, comparative study evaluating the safety and immunogenicity of Biological E's live, attenuated Measles-Rubella vaccine in 9–12 month old healthy infants
-
Published:2023-12
Issue:
Volume:36
Page:101232
-
ISSN:2451-8654
-
Container-title:Contemporary Clinical Trials Communications
-
language:en
-
Short-container-title:Contemporary Clinical Trials Communications
Author:
Thuluva Subhash,
Gunneri SubbaReddy,
Turaga KishoreORCID,
Mogulla Rammohan Reddy,
Yerroju Vijay,
Peta Kalyankumar,
Suneetha Pothakamuri Venkata,
Matur Ramesh V.
Subject
Pharmacology,General Medicine
Reference22 articles.
1. Measles;Moss;Lancet,2017
2. Rubella;Lambert;Lancet,2015
3. A dangerous measles future looms beyond the COVID-19 pandemic;Durrheim;Nat. Med.,2021
4. Rubella;Winter;Lancet,2022